AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.
More Articles...
- Coverage of the 2017 AASLD Liver Meeting
- AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?